ArticleBiotechnology journal2026
Integrated Fermentation Engineering Enables High-Level Leghemoglobin Production in Kluyveromyces marxianus via Metabolic Rewiring of Central Carbon Metabolism and Amino Acid Utilization.
Article in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Leghemoglobin (LBA), a hemoprotein critical for food industry applications, faces production challenges in microbial systems due to inefficient heme-globin assembly and metabolic constraints. Here, the food-safe yeast Kluyveromyces marxianus Tra-23 was validated as an excellent chassis, demonstrating robust growth and high LBA expression in bioreactor cultivation. Subsequently, key fermentation parameters-including medium composition, pH, temperature, and feeding strategy-were systematically optimized to enhance LBA biosynthesis. In 5-L bioreactors, the optimized processes elevated the LBA titer to 10.1 g/L, representing a 64.7% increase over initial conditions (6.13 g/L). Additionally, the specific glucose consumption rate (q
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.